| Promacta Could Ease Hepatitis C Treatment Complications |
 |
 |
 |
|
Friday, 18 November 2011 08:54
|
|
Depending on the results of a study investigating Promacta for Hepatitis C blood-related treatment complications, this medication could become a valued addition to managing the side effects of Hepatitis C combination therapy. Glaxo's Promacta May Turn Into Blockbuster Medicine, UBS Says By Makiko Kitamura Nov. 7 (Bloomberg) -- GlaxoSmithKline Plc's Promacta blood disorder medicine may generate as much as $2 billion in annual sales if the U.K.'s largest drugmaker can expand its use to the treatment of a condition associated with hepatitis C, according to UBS AG. The medicine, already approved for sale in the U.S. to raise platelet counts in patients with a rare blood disorder, is being studied to extend use to patients with thrombocytopenia, a blood complication stemming from hepatitis C treatments. Glaxo will present results from the last of three stages of clinical testing required for regulatory approval on the new use at a medical meeting in San Francisco today. Continue reading this entire article: http://www.hepatitis-central.com Add this page to your favourite Social Bookmarking websites;         
  |
